Adma Biologics (ADMA) Notes Payables (2011 - 2021)

Adma Biologics has reported Notes Payables for 8 years, with the latest figure at $100.0 million in Q1 2021.

• For the quarter ending Q1 2021, Notes Payables changed N/A year-over-year to $100.0 million; the trailing twelve-month figure through Mar 2021 stood at $100.0 million (changed N/A YoY), and the FY2020 full-year result was $100.0 million, up 37.93% from the prior year.
• Notes Payables for Q1 2021 stood at $100.0 million, roughly flat from $100.0 million in the prior quarter.
• The five-year high for Notes Payables was $100.0 million in Q4 2020, with the low at $6.7 million in Q1 2017.
• Historically, Notes Payables has averaged $57.3 million across 5 years, with a median of $72.5 million in 2019.
• Annual changes were most pronounced in 2017 — Notes Payables sank 63.07% — and 2019, when it soared 141.67%.
• Adma Biologics' Notes Payables stood at $30.0 million in 2017, then changed by 0.0% to $30.0 million in 2018, then jumped by 141.67% to $72.5 million in 2019, then jumped by 37.93% to $100.0 million in 2020, then changed by 0.0% to $100.0 million in 2021.
• The last three Notes Payables figures came in at $100.0 million (Q1 2021), $100.0 million (Q4 2020), and $85.0 million (Q3 2020), per Business Quant data.